U.S. Chemicals Stock News

With a price-to-earnings (or "P/E") ratio of 26.2x Life Time Group Holdings, Inc. ( NYSE:LTH ) may be sending bearish...

Unfortunately for some shareholders, the Baird Medical Investment Holdings Limited ( NASDAQ:BDMD ) share price has...

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Tyler Technologies (NYSE:TYL) has had a rough three months with its share price down 15%. However, the company's...

Pacira BioSciences, Inc. ( NASDAQ:PCRX ) shareholders may have reason to be concerned, as several insiders sold their...

It is doubtless a positive to see that the Loop Industries, Inc. ( NASDAQ:LOOP ) share price has gained some 42% in the...

This week we saw the Neonode Inc. ( NASDAQ:NEON ) share price climb by 11%. But that doesn't change the fact that the...

Thinking about what to do with MAC Copper stock? You are not alone. The company’s recent price trajectory has caught the eye of both cautious investors and optimistic speculators. In the last year, the stock slipped by 12.2%, but look further back and the story changes. MAC Copper is still up 24.4% over the last three years and an impressive 15.7% so far this year. If you have been watching for signs of life after a slow month or two, the near-flat 30-day and 7-day returns show the market...

Ovid Therapeutics has grabbed investor attention after unveiling encouraging Phase 1 results for its next-generation epilepsy drug, OV329. In addition to the promising data, the company secured $175 million in new financing, extending its cash runway. See our latest analysis for Ovid Therapeutics. After surging on the back of positive Phase 1 data and a major private financing announcement, Ovid Therapeutics has seen renewed bullishness, with momentum building over the short term. While the...

If you’ve been wondering whether now is the right time to buy, sell, or just keep an eye on Marcus & Millichap stock, you’re not alone. The real estate services company has had a bumpy ride recently, and investors are looking for direction. After closing at $28.89, Marcus & Millichap has moved down 2.4% in the past week, dropping 12.8% over the last month, and showing a year-to-date loss of 22.8%. Even over the past twelve months, shares are down 18.1%, although the five-year story is just...

In the past three months, Waterdrop (NYSE:WDH) experienced strong share market momentum, supported by a 65% increase in net income over the last five years despite return on equity lagging the industry average. Management’s choice to reinvest a high proportion of profits signals a focus on business expansion, even as analysts anticipate earnings growth to moderate going forward. We'll explore how Waterdrop's emphasis on reinvestment and earnings growth could reshape its investment narrative...

If you’re staring at Encompass Health’s ticker and wondering whether now is the time to buy, sell, or simply hold, you’re definitely not alone. The stock world seems to have taken a close look at this healthcare heavyweight lately. The past week and month haven’t exactly shown fireworks, with the stock dipping 2.1% and 1.9% respectively. If you zoom out, it’s not hard to spot the strong uptrend. Year-to-date, Encompass Health is up a remarkable 34.2%, and the one-year return comes in at...

Thinking about what to do with American Healthcare REIT stock? You are not alone. With a year-to-date climb of 47.4% and an impressive 69.0% boost over the past year, plenty of investors are weighing whether its run has staying power or if the easy money has already been made. Of course, not every movement has been straight up. Over the past 7 days, the stock is down 2.1%, and over the past month, it has slid 4.3%. These short-term dips have been matched by shifts across the broader...

If you’re here, you’re probably weighing the pros and cons of holding onto, buying, or maybe even selling Essential Utilities stock. You’re not alone. Plenty of investors are keeping a close watch on this company, drawn in by its track record and the recent rhythm of its share price. Over the last week, Essential Utilities inched up by 0.7%, which could signal growing optimism, while its nearly flat 30-day return of 0.1% suggests the market is still sizing up its next move. Zoom out to the...

If you are watching eXp World Holdings these days, you are likely trying to figure out whether to double down, hit pause, or pivot. The stock has felt the heat this year, slipping by 5.3% so far in 2024, following a tough year with a 17.2% drop and an even steeper 61.3% decline over five years. After a brief uptick in late spring, shares have softened again, closing recently at $10.74. Some of this choppiness can be tied to shifting market sentiment around real estate tech and renewed debates...

Trying to decide what to do with Federal Agricultural Mortgage stock can feel like you are standing at a crossroads, especially when the price movements have been anything but subtle lately. After hitting a peak earlier in the year, the stock recently dipped by 3.4% in the past week and a notable 20.6% over the last month. Year to date, it is still down 15.1%, and looking back over the past year, the slide totals 8.1%. If you zoom out, the story changes dramatically. Over the last five years,...

If you are wrestling with whether to buy, sell, or simply hold onto Altice USA, you are not alone. The stock can feel a bit like a rollercoaster lately, especially with those recent price swings. Over just the past 7 days, Altice USA notched a gain of 5.9%, adding to the 11.6% bump in the last month. Zooming out a bit, year-to-date returns are up 5.5%, and over the last 12 months, shares gained 4.6%. If you have been invested longer term, though, those multi-year losses might still sting,...

If you are grappling with what to do about Petco Health and Wellness Company stock, you are far from alone. The last few years have been rocky terrain for this pet care retailer, with shares tumbling by around 64% over three years and down nearly 26% in the past twelve months. And yet, there have been some flashes of green. Over the last week, shares rebounded 5.5%, and the past month has seen a modest climb of 4.4%. These short-term bumps suggest investors are beginning to rethink the...

If you have First Bancorp in your portfolio or on your watchlist, you're probably wondering if now is the right moment to act, hold, or move on. The stock has shown quite the journey recently. After a slight 1.5% dip over the last week and a 5.6% slide in the past month, it is still up an impressive 21.7% since the start of the year, not to mention a massive 151.9% gain over the last five years. Clearly, there has been real momentum here, but also some near-term volatility that has left...

Deciding what to do with Affiliated Managers Group right now? You’re not alone—investors have had plenty to think about with this stock lately. Its share price has done more than just tread water, climbing 1.8% over the last week, 5.5% in the past month, and a striking 30.0% since the start of the year. If you had bought in five years ago, you’d be looking at gains of 216.1%. Clearly, Affiliated Managers Group has been on the move, and those moves have not gone unnoticed as the market keeps...

If you have been eyeing SmartStop Self Storage REIT lately and wondering what your next move should be, you are certainly not alone. The stock recently closed at $35.94, and while it is up an impressive 9.7% year-to-date, the last month has seen some pullback with a 3.7% decline and a similar 3.5% dip just last week. These short-term moves may reflect not just shifting market sentiment but also investors reassessing risk and growth prospects as the broader real estate sector evolves. For...

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

If you have Arcus Biosciences on your radar right now, you are not alone. Plenty of investors are asking themselves whether this biotech stock is about to turn a corner after a stretch of underperformance, or if there is more volatility ahead. With the share price closing at $13.35 and eking out a modest 0.2% gain over the last week, it might not look like much is happening. However, dig a little deeper and there are some interesting sparks. Over the past month, Arcus Biosciences returned...